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China reported a novel coronavirus, phylogeneticallyrelated to severe acute respiratory syndrome coro-navirus (SARS-CoV), as the causative agent of anoutbreak of pneumonia of unknown etiology in
Wuhan.WorldHealthOrganization declaredCoronavirus disease
2019 (COVID-19) a global pandemic: nowadays, 4,864,881 cases
were reported worldwide, 228,006 in Italy with a 14% mortality
rate.1 Retrospective studies on Chinese patients with pneumonia
highlighted that cardiovascular diseases, older age, highC-reactive
protein (CRP), interleukin-6 and ferritin, low lymphocytes and
secondary infections were predictive of death.2,3
COVID-19 features in immunocompromised hematological
patients are emerging, but data on allogeneic hematopoietic stem
cell transplant (allo-HSCT) recipients are still scanty (Table 1).4–8
Jin et al reported a case of pneumonia in a male with chronic
lymphocytic leukemia successfully treated with chemotherapy,
corticosteroids and a-interferon.4 Zhang et al described another-
one in a myeloma patient with favorable outcome after
corticosteroids, arbidol and tocilizumab.5 COVID-19 in an
allo-HSCT recipient, developed 7-months after transplant while
on maintenance cyclosporine, was firstly published by Huang
et al. Despite achieving negative SARS-2-CoV with lopinavir/
ritonavir, corticosteroid and immunoglobulins, the patient died
with persistently low lymphocytes (T-cell <300/mL, CD4<100/
mL) and secondary infection.6 Malard et al reported 25 cases in
hematological patients including 2 recipients of allo-HSCT. At a
median follow-up of 29-day since symptoms onset, 52% of
patients developed acute respiratory distress syndrome (ARDS)
and 36% died.7 The first case series on 6 allo-HSCT recipients,
who developed COVID-19 at a median time of 41-months after
HSCT, did not report deaths, suggesting that an immunosup-
pressed status [5/6 patients with chronic graft-vs-host disease
(c-GVHD)] may be protective against hyper-inflammation of
severe disease (unpublished data).
We described a case of severe low respiratory tract infection
(LRTI) by SARS-2-CoV in a 64 years-old man with non-Hodgkin
lymphoma,which arose on21-day after allo-HSCT frommatched-
unrelated donor, whose pre-engraftment phase was uneventful.
At hospital admission, 3 days after previous discharge, he was
febrile and piperacillin/tazobactam was introduced. Laboratory
tests revealed WBC 3490/mL (neutrophils 2000/mL, lymphocytes
500/mL), platelets 189/mL, CRP 13mg/dl, lactic dehydrogenase
710U/l, normal renal and hepatic functions. The nasopharyngeal
swab was negative for community acquired respiratory viruses
(CARV), while PCR for SARS-2-CoV resulted positive on 26-day
after HSCT with CT scan revealing mild pneumonia (Fig. 1A).
The same day lopinavir/ritonavir and hydroxychloroquine were
introduced, discontinuing piperacillin/tazobactam. At this time,
the patient was in good condition [Modified EarlyWarning Score
(MEWS) 2 points]. Laboratory tests showed CRP 1mg/dl, lactic
dehydrogenase 591U/l, bilirubin 1mg/dl, ferritin 5510ng/ml,
pro-calcitonin 0.1ng/ml, D-dimer 0.83ng/ml, WBC 1720/mL
(neutrophils 800/mL, monocytes 200/mL, lymphocyte 600/mL,
CD435/mL, CD8304/ mL, CD190/mL). On 33-day, because
of major pharmacological interactions, lopinavir/ritonavir was
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replacedwith azithromycin and cyclosporinewithmycophenolate,
detecting cyclosporine serum values ≥200ng/ml until 43-day. On
36-day clinical condition worsened (MEWS 3 points), inflamma-
tory markers increased (ferritin 5342pg/ml, lactic dehydrogenase
836U/l, D-dimer 0.71ng/ml) and CT scan showed worsening
bilateral infiltrates (Fig. 1B). Therefore, he received a single6mg/kg
dose of tocilizumab and started methylprednisolone 0.5mg/kg
obtaining fever resolution. COVID-19 rapid immune-chro-
matographic test for determination of antibodies in whole blood
was performed revealing the absence of both IgG and IgM. The
patient required a progressive increase of oxygen supply, starting
non-invasive ventilation on 41-day (MEWS 5 points). The same
day, laboratory tests showed bilirubin 3.3mg/dl, lactic dehydro-
genase 1651U/l and haptoglobin 0mg/dl. Because of suspected
endothelial activation, probably driven by both thromboticmicro-
angiopathy and pulmonary hyper-inflammation, an off-label
administration of intravenous defibrotide 6.25mg/kg q6h was
started and methylprednisolone was increased to 1mg/kg
achieving a decrease of lactic dehydrogenase and stabilization of
bilirubinemia and respiratory failure without major and minor
bleedings. Since hospital admission, the patient received primary
antimicrobial prophylaxis with acyclovir, letermovir, atovaquone
and isavuconazole. On 45-day, SARS-2-CoV PCR was still
positive, so azithromycin and hydroxychloroquine were discon-
tinued. The clinical course was complicated on 54-day by blood
culture negative septic shock (MEWS 8 points), requiring transfer
to IntensiveCareUnit for invasivemechanical ventilation, inotrope
support (adrenaline, noradrenaline) and empiric antibiotic therapy
(meropenem, daptomycin); the same day defibrotide was discon-
tinued (bilirubin 3mg/dl, lactic dehydrogenase 880U/l). After
Ethical Committee approval, on 57-day, the patient received
remdesivir 100mg q24h for compassionate use. Despite a prompt
resolutionof septic shockand requirementofmoderatemechanical
ventilation support for extensive bilateral pneumonia (Fig. 1C), a
consciousness impairment and hepatic failure have taken over in
the next days. Thrombotic micro-angiopathy, GVHD and viral
Table 1
Published Clinical Reports of Coronavirus Disease 2019 in Hematological Patients.
Reference
Location
Age (years)/Sex
Hematological disease
Hematological status
Hematological treatment
Previous
transplant
Ongoing
corticosteroids
Comorbidities
Time between
symptoms
onset-diagnosis
(days)
Radiological
diagnosis
ARDS
Invasive mechanical
ventilation
COVID-19 management
Follow-up since
symptoms onset
(days)
Survival status
Jin et al
China4
39/male
Non Hodgkin lymphoma/CLL
Complete remission/Binet Stage C
None, 2 months after chlorambucil withdrawn
No
No
No
4
Positive CT scan
Yes
No
Chlorambucil, nebulized
a-IFN, Ig, MPD
22
Alive
Zhang et al
China5
60/male
Multiple myeloma
Complete remission
Maintenance thalidomide after 2 VTD cycles
No
No
No
20
Positive CT scan
No
No
Umifenovir, MPD, TCZ
42
Alive
Huang et al
China6
51/male
AML
Complete remission
HSCT, 7 months before
Yes, HSCT
No
No
3
Positive CT scan
Yes
Yes
LPV/r, Ig, MPD
22
Dead
∗
Malard et al
France7
Twenty-five patients: median age 72/68% male
80% lymphoid tumor, 16% myeloid tumor
40% complete remission, 24% progression
52% ongoing, 16% supportive care
Yes, 2 HSCT†, 6 ASCT
Yes, 40%
68% hypertension,
32% obesity,
8% COPD
4 (range: 0-22)
Positive CT scan: 56%
Yes, 52%
Yes, 24%
Supportive care 72%,
TCZ 12%, LPV/r 16%
29 (range: 14–40)
Alive 64%, Dead 36%
Li et al
China8
Five patients: 47 (range: 41–89)/60% male
100% chronic myeloid leukemia
40% no complete hematological response,
40% major molecular response
60% imatinib, 20% flumatinib, 20% HQP1351
No
No
40% hypertension,
20% diabetes
Not available
Positive CT scan: 80%
Yes, 20%
Not available
Not available
16 (range: 11–40)
Alive 80%, Dead 20%
Lupo Stanghellini et al
Italy (submitted data)
Six patients: median age 50 (range: 32–63)/
66% male
100% myeloid tumor (5 AML, 1 MDS)
100% complete remission
100% HSCT, median time after HSCT
41-months (range: 30–114)
Yes, 6 HSCT (4 MUD,
2 MMRD)‡
No
50% hypertension,
33% COPD
3 (range: 0–47)
Positive CT scan: 50%
No
No
LPV/r and HCQ 50%,
anakinra 16%
42 (range : 39–50)
Alive 100%
AML = acute myeloid leukemia, ARDS = acute respiratory distress syndrome, ASCT = autologous stem cell transplant, CLL = chronic lymphocytic leukemia, COPD = chronic obstructive pulmonary disease,
COVID-19 = Coronavirus disease 2019, CT = computed tomography, HCQ = hydroxychloroquine, HSCT = hematopoietic stem cell transplant, IFN = interferon, Ig = immunoglobulin, LPV/r = lopinavir/ritonavir,
MDS = myelodysplastic syndrome, MMRD = mismatched-related donor, MPD = methylprednisolone, MUD = matched-unrelated donor, TCZ = tocilizumab, VTD = bortezomib-thalidomide-dexamethasone.
∗
COVID-19 onset while on maintenance cyclosporine; despite achieving negative SARS-CoV-2, the patient died with persistently low lymphocytes (T-cell <300/mL, CD4<100/mL) and secondary infection.
† 40 years-old female who developed COVID-19 ARDS 9-months after HSCT, alive 23-days after symptoms onset on invasive mechanical ventilation; 61 years-old male who developed COVID-19 ARDS 3-months
after chimeric-antigen receptor T-cell therapy (previous ASCT, previous HSCT), alive 38-days after symptoms onset on invasive mechanical ventilation.
‡ 5/6 patients with chronic graft-vs-host disease, 2/5 ruxolitinib, 1/5 imatinib/methotrexate, 2/5 no systemic immunosuppressive therapy.
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infections have been addressed in differential diagnosis, but none
was deemed likely for absence, respectively, of schistocytes and
renal impairment, gut and skin involvement and viral reactivations
(Cytomegalovirus, Herpes-virus 6 and Adenovirus). On 64-day
a sharply increase of bilirubinemia up to 17mg/dl required
interruption of both remdesivir and letermovir in suspicion of
drug-induced liver injury. Radiological findings on 66-day showed
moderate increase of ground-glass opacities (Fig. 1D). The same
day high plasmatic concentration of isavuconazole (10mg/L) was
detected, so the drug was withdrawn, being partially responsible
for liver damage. On 74-day, bronco-alveolar lavage was
performed excluding secondary infections (CARV, Cytomegalo-
virus, Pneumocystis, aspergillosis, bacteria) with SARS-2-CoV
persistently positive, being the only causative pathogen. Bilirubi-
nemia decreased slightly to 13mg/dl and isavuconazole plasmatic
concentration was still 4mg/L. On 75-day, galactomannan on
bronco-alveolar lavagewas repeated resulting positive (from<0.5
to 3.3). Despite maximal medical and resuscitation support, the
patient died on 78-day.
Several efforts are ongoing to address COVID-19 clinical
features and therapeutic options in solid organ transplant (SOT)
and HSCT recipients.
An Italian experience on renal transplant recipients reported a
mortality rate of 25% (5/20) despite 95%, 55%, and 30% of
patients received HIV protease-inhibitors, dexamethasone and
tocilizumab, respectively.9 The Spanish observation on 18 SOT
recipients [kidney (44.4%), liver (33.3%), heart (22.2%)], who
developed COVID-19 at a median interval since transplantation
of 9.3 years, reported a fatality rate of 27.8%.10 Another Italian
report showed a high-mortality in long-term liver transplant
recipients (>10 years): 3% (3/111) acquired pneumonia and all
died. Conversely, 7.5% (3/40) of short-term liver transplant
recipients (<2 years) experienced an uneventful course of disease.
Interestingly, only 10% of long-term liver transplant recipients
Figure 1. (A) 26-day after transplant, 5-day after symptoms onset: mild pseudo-nodular thickeningswith ground-glass opacities affecting the lower
lobes sub-pleural lung parenchyma and patchy ground-glass opacities at the upper left lobe. (B) 36-day after transplant, 15-day after symptoms
onset: peripheral ground-glass opacities associated with smooth interlobular and intra-lobular septal thickening (crazy-paving pattern) at the
upper lobes mainly the left one, mild increase of ground-glass opacities affecting the lower lobes. (C) 59-day after transplant, 38-day after
symptoms onset: extensive ground-glass opacities in both lungs, involving almost the entire lung parenchyma but the upper right lobe, mild
bilateral pneumothorax and moderate pneumo-mediastinum, absence of acute pulmonary thromboembolism. (D) 66-day after transplant, 45-day
after symptoms onset: extensive ground-glass opacities in both lungs, involving almost the entire lower lobes andmost of the upper lobes, giving a
white lung appearance, with air bronchograms at lower lobes; resolution of pneumothorax and pneumo-mediastinum, presence of pneumatocele
at the lingula; absence of acute pulmonary thromboembolism, pleuro-pericardial effusion and mediastinal lymphadenopathies.
(2020) 4:4 www.hemaspherejournal.com
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had a full immunosuppressive therapy (IST) and a higher
proportion of them displayed risk factors for COVID-19
mortality, such as hypertension, cardiovascular disease, chronic
renal failure, older age.11
In allo-HSCT setting, it is plausible that acquiring COVID-19 in
late post-engraftment phase, after achieving a good T and B-cell
immune-recovery, may not affect the outcome. Probably IST in the
context of c-GVHD could prevent the transition from pro-
inflammatory towards anti-inflammatory wound-healing macro-
phages reaction, which usually promote the typical lung tissue
damage of ARDS. In our report, since a therapeutic serum level
has been maintained until 43-day, we would exclude any role of
cyclosporine withdrawal with the hyper-inflammatory rate
observed starting from 36-day. For allo-HSCT recipients, we
assume that pre-engraftment and early post-engraftment phases
are the timeframe at higher risk for fatal outcome due to severe
lymphopenia and high risk of progression to LRTI by CARV.12
Our case suggests, also, an atypical radiological evolution of SARS-
2-CoV pneumonia in HSCT recipients, persisting for over 6-weeks
since presentation of a predominately crazy-paving ground-glass
opacities pattern without evolution in the consolidation phase.13
This finding may be due to the onset of pneumonia within 30-day
after allo-HSCT with anti-thymocyte globulin as part of
conditioning regimen, which justifies the absence of acquired
immunity determining a persistent viral replication in low
respiratory tract, probably resulting in a prolonged virus-induced
cytopathic effect. Considering the pivotal role of IL-6 cascade
resulting in a cytokine-realized syndrome and of endothelium
damage resulting in a pro-coagulative status, the administration of
both tocilizumab and defibrotide could at least have contained the
inflammatory lung tissue damage. Allo-HSCT setting exposes the
recipient in pre-engraftment and early post-engraftment phase to a
profound degree of immunosuppression that prevents him from
containing virus spread resulting in a severe clinical course andhigh
risk of mortality, due also to the absence of an effective antiviral
therapy. The use of convalescent plasma should be evaluated in
immunocompromisedhosts to replace impairedantibody response.
In conclusion, we report the first case of SARS-2-CoV
pneumonia in early post-engraftment phase of allo-HSCT.
Facing a complicated clinical course, despite the administration
of almost all available therapeutic options except for conva-
lescent plasma against SARS-2-CoV, including the experimental
agent remdesivir, we have not succeeded in containing viral
replication resulting in patient’s death, which was also ultimately
due to breakthrough invasive aspergillosis. In the context of a
global pandemic, our experience confirms the role of screening
allo-HSCT candidates for SARS-2-CoV infection, as recently
stated by European BoneMarrow Transplantation society.14 For
those who test positive, a careful transplant planning delaying the
procedure is critical to both limit the risk of progression to severe
LRTI in pre-engraftment phase and ensure an optimal care of
hematological malignancy.
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